Relay Therapeutics, Inc. (RLAY) Income Statement

The revenue line is highly erratic, with quarters like 2025Q3 and 2024Q4 showing zero revenue, while others show small amounts likely from collaborations or grants. This pattern suggests that top-line growth is not a reliable indicator of operational progress; instead, it underscores the company's dependence on external partnerships. Investors should monitor the timing and size of collaboration milestones, as they drive reported revenue but do not reflect core business scalability.

The gross margin figures are heavily distorted by the inclusion of large COGS line items in quarters with minimal or zero revenue, such as $67.9M in 2025Q3 and $92.0M in 2024Q2. These charges likely represent cost of collaboration revenue or milestone payments, not traditional product costs. As a result, gross margin analysis is not meaningful for assessing pricing power or cost efficiency; instead, investors should focus on R&D and SG&A trends.

The company's operating income is consistently negative, and the gap between gross profit and operating income is driven by substantial R&D spending, which has grown from $55.4M in 2025Q4 to $76.5M in 2026Q2. This suggests that the company is deliberately scaling its research efforts, likely to advance its pipeline, but this is resulting in a deteriorating operating margin. The lack of revenue growth to offset these costs means that operating leverage is unlikely to materialize in the near term.

The cost structure is heavily weighted toward R&D, which accounts for over 80% of total operating expenses in most quarters. SG&A has been relatively stable, ranging from $11.0M to $20.6M, suggesting disciplined overhead management. However, the consistent escalation in R&D spending, from $68.1M in 2024Q4 to $76.5M in 2026Q2, indicates that the company is prioritizing pipeline advancement, which is typical for a clinical-stage biotech but raises concerns about cash runway.

The fourth quarter of 2025 showed a notable reduction in operating loss, driven by lower R&D spending ($55.4M) and a slight uptick in revenue ($7.0M). This could indicate a strategic pause in investment or timing of expenses. However, the subsequent quarters in 2026 saw R&D spending rebound to $76.5M, erasing that improvement. This inflection point highlights the volatility in spending patterns and suggests that management may be adjusting investment levels based on pipeline milestones, but the overall trend remains one of escalating cash burn.